Opinion|Videos|January 19, 2026
Addressing Access Barriers and Formulary Restrictions
Panelists discuss how addressing payer restrictions and leveraging data-driven advocacy are essential for timely access to care.
Advertisement
Episodes in this series
Panelists discuss how payer-imposed step edits and prior authorizations continue to delay patient access to needed treatments. These administrative barriers often exacerbate symptom relapse and caregiver strain.
Panelists discuss how providers rely on real-world evidence and outcomes data to justify coverage approvals and ensure continuity of care.
Panelists discuss how policy reform and closer collaboration between clinicians, payers, and advocacy groups can streamline access and reduce inequities.
Advertisement
Related to this article
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
Insurance Barriers Tied to Missed Long-Acting PrEP Starts
4
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
5